Antisense Oligonucleotide Drug Class List

Drugs in Drug Class: Antisense Oligonucleotide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	8,101,743		Y	Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	10,683,499		Y	Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes	9,127,276			Y

Market Dynamics and Patent Landscape for Antisense Oligonucleotides (ASOs)

Last updated: January 14, 2026

Executive Summary

Antisense oligonucleotides (ASOs) represent a rapidly evolving segment within molecular medicine, characterized by innovative therapeutic mechanisms aimed at selectively modulating gene expression. The global ASO market is estimated to grow from USD 1.2 billion in 2023 to approximately USD 6.5 billion by 2030, driven by advances in nucleic acid chemistry, mounting approvals, and expanding therapeutic indications.

The patent landscape features dominant players such as Ionis Pharmaceuticals (now part of AstraZeneca), Biogen, and Novartis, with a proliferation of patents covering chemical modifications, delivery systems, and specific drug candidates. Patent disputes and expiration cycles critically influence market access and innovation trajectories.

This comprehensive review offers insights into the market dynamics, competitive landscape, key patents, regulatory factors, and future trends shaping the ASO drug class globally.

---

1. What Are Antisense Oligonucleotides?

Definition & Mechanism

Antisense oligonucleotides are short, synthetic single-stranded nucleic acids designed to bind selectively to target messenger RNA (mRNA). Binding induces degradation (via RNase H), splicing modulation, or translation inhibition, thereby reducing or altering protein expression.

Parameter	Details
Typical length	18–25 nucleotides
Chemical modifications	Phosphorothioate backbone, 2'-O-methyl, 2'-MOE, locked nucleic acids (LNAs)
Delivery methods	Intravenous, subcutaneous, intrathecal
Approved drugs	Eteplirsen, Nusinersen, inotersen, mipomersen, others

Key Therapeutic Areas: Rare genetic disorders, neurodegenerative diseases, cancers, infectious diseases, and cardiometabolic conditions.

---

2. How Big Is the Market for ASOs Currently and What Is Its Growth Outlook?

Year	Estimated Global Market Size (USD billions)	CAGR (Compound Annual Growth Rate)	Sources
2023	1.2	—	[1]
2025	2.3	~30%	[2]
2030	6.5	~35%	[3]

Driving Factors:

• Regulatory approvals: Since the approval of Vyondys 53 (golodirsen, 2019), multiple ASOs received marketing authorizations.
• Pipeline expansion: Over 100 ASO candidates in clinical stages across diverse indications.
• Technological innovation: Advances in chemical modifications enhance stability, affinity, and delivery.
• Unmet medical needs: Particularly in rare and genetic diseases with limited treatment options.

Market Segmentation:

Segment	Market Share (2023)	Key Companies	Notable Drugs
Rare genetic disorders	45%	Ionis, Biogen, Novartis	Spinraza, Exondys 51, Firdapse
Neurodegenerative diseases	25%	Biogen, Ionis	Nusinersen, inotersen
Oncology	15%	Moderna, AstraZeneca	Upcoming candidates
Infectious diseases	10%	GSK, Moderna	Novel candidates under development
Others	5%	Various	Emerging applications

---

3. Who Are the Major Players Driving the ASO Market?

Company	Core Focus Areas	Key Patents (select)	Notable Drugs
Ionis Pharmaceuticals	Pioneers in ASO design & platform technology	Multiple patents for backbone modifications, delivery	Spinraza, Tofersen,way2 ASO Platform
Biogen	Neurology, rare genetic diseases	Patents on specific chemical modifications, delivery systems	Spinraza, BIIB067 (risdiplam)
Novartis	Oncology, rare diseases	Patent filings covering chemical modifications and conjugates	Leqvio (inclisiran)
GSK	Infectious diseases, rare genetic conditions	Patents on conjugation strategies and chemical modifications	GSK2831502A (candidate)
Moderna	Infectious disease, personalized medicine	Proprietary delivery and modification platform	Investigational ASOs

Patent Strategy Trends:

• Extensive patenting of chemical modifications (e.g., LNAs, 2'-O-methyl).
• Delivery innovations, such as lipid conjugates or nanoparticles.
• Sequence-specific patents to protect therapeutic targets.
• Defensive patents to extend exclusivity.

---

4. What Are the Key Patent Landscape Trends?

Patent Filing & Grant Trends (2010–2023):

Year	Number of Patent Families	Notable Patent Applicants	Focus Areas
2010–2015	150	Ionis, Génzyme, Alnylam	Chemical modifications, delivery systems
2016–2018	250	Novartis, GSK, Roche	Conjugation strategies, specific sequences
2019–2023	400+	Multiple new entrants	Next-generation modifications, delivery platforms, new indications

Key Patent Categories:

Category	Description	Examples
Chemical Modifications	Backbone and sugar modifications for stability	Phosphorothioate, 2'-MOE, LNA
Delivery Systems	Conjugates and nanoparticles	GalNAc conjugates, liposomal formulations
Target-Specific Sequences	Patent claims on particular nucleotide sequences	Disease or gene-specific sequences
Manufacturing Processes	Synthesis and purification improvements	Solid-phase synthesis, purification methods

Patent Expiry & Impact:

• Many foundational patents filed between 2000–2010 are expiring from 2025 onward, providing opportunities for generics and biosimilars.
• Strategic patenting now focuses on next-gen modifications, delivery, and target-specific claims for market exclusivity.

---

5. How Do Regulatory and Policy Frameworks Impact Market Dynamics?

• FDA and EMA Approvals: Accelerated approval pathways (e.g., Priority Review, Breakthrough Therapy) have facilitated quicker access for ASOs like Spinraza (2016, FDA) and Waylivra (2019, EMA).

• Orphan Drug Designation: Over 50% of approved ASOs hold orphan status, incentivizing R&D investments.

• Patent Linkage & Data Exclusivity: Market exclusivity periods of up to 12 years under certain conditions delay biosimilar ANDA filings.

• Pricing & Reimbursement: High development costs (estimates up to USD 1.3 billion per approved drug, [4]) influence pricing strategies, with payers demanding value-based pricing and real-world evidence.

---

6. What Future Trends Will Shape the ASO Market?

Trend	Impact & Opportunities
Next-Generation Chemical Modifications	Enhanced stability, reduced immunogenicity, broader target scope
Improved Delivery Technologies	Increased tissue-specific delivery, CNS penetration
Expansion into New Indications	Oncology, infectious diseases, and rare metabolic disorders
Digital & AI-Driven Design	Accelerated candidate discovery, structure-function optimization
Regulatory Evolution	Clearer pathways for complex oligonucleotide approval

---

7. How Do Comparative ASO Technologies and Drug Candidates Differ?

Criteria	First-generation ASOs	Next-generation ASOs
Chemical modifications	Phosphorothioate backbone only	Multiple modifications (LNA, constrained ethyl)
Delivery strategy	Naked administration	Conjugates, nanoparticles
Target tissue delivery	Limited	Enhanced tissue-specific delivery
Immunogenicity	Higher risk	Lower due to chemical modifications
Efficacy	Variable	Improved with chemical/ delivery innovations

---

Key Takeaways

• Market Growth: The ASO market is poised for exponential growth, driven by technological advances, expanded indications, and regulatory support.
• Patent Landscape: Dominated by innovations in chemical modifications, delivery systems, and target-specific claims, with upcoming patent expirations opening opportunities for new entrants.
• Competitive Strategy: Companies invest heavily in chemical, delivery, and sequence patents to achieve exclusivity.
• Regulatory Environment: Favorable pathways accelerate approval but also pressure pricing, necessitating demonstrable value.
• Future Trends: Expect next-generation modifications, targeted delivery, and AI-driven design to dominate the pipeline.

---

FAQs

Q1: How do chemical modifications influence the patentability and effectiveness of ASOs?
Chemical modifications such as 2'-MOE, LNAs, and phosphorothioate backbones enhance stability, affinity, and reduce immunogenicity, making them patentable and clinically advantageous.

Q2: What are the main patent challenges faced by new ASO entrants?
Existing patents on backbone chemistry, delivery platforms, and proprietary sequences pose significant barriers. Litigation and patent thickets can delay market entry.

Q3: How does the expiration of foundational patents affect the ASO market?
Patent expiries (starting around 2025) open routes for generics and biosimilars, increasing competition and potentially reducing costs.

Q4: What therapeutic areas are expected to see the most growth in ASO applications?
Rare genetic diseases, neurodegenerative disorders, and certain cancers are primary growth drivers, owing to high unmet needs and regulatory incentives.

Q5: Are there emerging regulatory pathways that could further accelerate ASO approvals?
Yes, mechanisms such as Breakthrough Therapy, Fast Track, and Orphan Drug Designation facilitate faster review processes, especially for high-need conditions.

---

References

1. MarketWatch. "Antisense Oligonucleotides Market Size, Share & Trends Analysis Report," 2023.
2. Grand View Research. "Antisense Therapeutics Market," 2024.
3. MarketsandMarkets. "Nucleic Acid Therapeutics Market," 2023.
4. Deloitte. "Cost of Developing a New Pharmaceutical," 2020.

---

This comprehensive analysis aims to inform strategic decision-making for stakeholders invested in the antisense oligonucleotide space, offering clarity into market drivers, competitive dynamics, and future prospects.